This week’s docket skews toward late-stage oncology follow-through rather than binary regulatory drama, with no PDUFA dates on the calendar and ARV’s involvement in three separate trials, including the ERADICATE prostate cancer study and a hepatocellular carcinoma combination readout, the throughline worth watching. IBRX’s bladder cancer combination and BIIB’s observational pregnancy safety data round out […]

Here’s what’s on the biotech calendar for September 20–September 27: 2 FDA decision dates, 1 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-22 IONS — NDA 2026-09-26 MIRM — NDA 🧪 Trial Catalysts & Milestones CRDL — 2026-09-21: CardiolRx in Recurrent Pericarditis (MAVERIC […]

Here’s what’s on the biotech calendar for September 13–September 20: 1 FDA decision dates, 2 trial catalysts, and 0 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-09-18 NUVL — adult patients with locally advanced or metastatic ROS1-posi NDA 🧪 Trial Catalysts & Milestones CORT — 2026-09-15: REVERSE: […]

This week’s biotech calendar is unusually quiet on the regulatory and earnings fronts, with no PDUFA dates or earnings reports scheduled. The lone catalyst worth watching is the SIGN study evaluating communicable disease assessment protocols for migrants in reception centers, a public health-focused readout rather than a commercial one. Expect thin newsflow and low volatility […]

Here’s what’s on the biotech calendar for August 30–September 6: 0 FDA decision dates, 15 trial catalysts, and 0 earnings reports from tracked companies. 🧪 Trial Catalysts & Milestones OSTX — 2026-08-30: LDRT Combined With Immunochemotherapy for Colorectal Cancer With Liver Metastasis OSTX — 2026-08-31: Venetoclax in Combination With ASTX727 for the Treatment of Chronic […]

Here’s what’s on the biotech calendar for August 23–August 30: 2 FDA decision dates, 4 trial catalysts, and 1 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-08-25 JAZZ — sBLA 2026-08-25 ZYME — adults with previously treated NDA 🧪 Trial Catalysts & Milestones OSTX — 2026-08-25: Study […]

Here’s what’s on the biotech calendar for August 16–August 23: 1 FDA decision dates, 1 trial catalysts, and 1 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-08-22 CAPR — rare diseases BLA 🧪 Trial Catalysts & Milestones ARV — 2026-08-20: Chemotherapy With or Without Immunotherapy for Peritoneal […]

Here’s what’s on the biotech calendar for August 9–August 16: 0 FDA decision dates, 3 trial catalysts, and 13 earnings reports from tracked companies. 🧪 Trial Catalysts & Milestones GILD — 2026-08-09: Accelerated ART Initiation for PWHIV Who Are Out of Care ACRV — 2026-08-12: Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors […]

Here’s what’s on the biotech calendar for August 2–August 9: 0 FDA decision dates, 2 trial catalysts, and 5 earnings reports from tracked companies. 🧪 Trial Catalysts & Milestones BIIB — 2026-08-06: A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Health ARV — 2026-08-08: Testing […]

Here’s what’s on the biotech calendar for July 26–August 2: 1 FDA decision dates, 14 trial catalysts, and 1 earnings reports from tracked companies. 💊 FDA Decisions (PDUFA Dates) Date Ticker Drug Indication Type 2026-07-29 OTLK — Wet AMD <P STYLE=”font: 10pt Times New Roma BLA 🧪 Trial Catalysts & Milestones OSTX — 2026-07-30: Intrathecal […]